Sugi Predict

Sugi Predict / Compounds / SCHEMBL4470893

SCHEMBL4470893

SCHEMBL4470893

Cc1ccc(S(=O)(=O)Oc2cccc3c(S(=O)(=O)NCc4c(F)cccc4F)cccc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ ESR1 P03372 2/20 0.52
▸ GAA P10253 2/20 0.52
▸ ESR2 Q92731 2/20 0.52
▸ NSD2 O96028 5/20 0.42
▸ CYP19A1 P11511 1/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ HTR6 P50406 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482026 0.84 CA12 (0.56) MEN1KMT2AESR1GAAESR2
SCHEMBL4483773 0.83 MEN1 (0.60) MEN1KMT2AESR1GAAESR2
SCHEMBL4483934 0.83 MEN1 (0.52) MEN1KMT2AESR1GAAESR2
SCHEMBL4492832 0.82 MEN1 (0.51) MEN1KMT2AESR1GAAESR2
SCHEMBL4492967 0.82 KMT2A (0.51) MEN1KMT2AESR1GAAESR2
SCHEMBL4482139 0.81 NSD2 (0.59) MEN1KMT2AESR1GAAESR2
SCHEMBL4479900 0.81 KMT2A (0.50) MEN1KMT2AESR1GAAESR2
SCHEMBL4473385 0.81 MEN1 (0.50) MEN1KMT2AESR1GAAESR2
SCHEMBL4492987 0.81 MEN1 (0.47) MEN1KMT2AESR1GAAESR2
SCHEMBL4483280 0.80 CYP19A1 (0.50) MEN1KMT2AESR1GAAESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 MEN1 4507/4885KMT2A 1012/4885ESR1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.